A Clinical Stage Biotechnology Company Specialising In Cell Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Key Highlights: Cynata to collaborate with Leiden University Medical Center (LUMC) in the Netherlands, in a new clinical trial in patients who have received a kidney transplant Trial to be funded by LUMC; Cynata will supply iPSC-derived Cymerus mesenchymal stem cells (MSCs) at its cost to facilitate the trial and has full commercial rights There are approximately 130,000 kidney transplants around the world each year. Kidney transplantation is life-saving in patients with chronic renal failure and frees the patient from the need for dialysis. Currently, lifelong immune suppressive therapy is required in renal transplant patients to reduce the risk of rejection. This can lead to increased risk of infections and cancer and the main anti-rejection drugs are also directly toxic to the kidneys In previous clinical trials, mesenchymal stromal/stem cells have shown potential to enable the early withdrawal of anti-rejection drugs in renal transplant recipients without increased rejection and wi ....

Cynata Cymerus Mscs , Ross Macdonald , Cymerus Mscs , Leiden University Medical Center , Head Of The Department Internal Medicine , Department Of Nephrology , Cynata Therapeutics Limited , Key Highlights , Mesenchymal Stromal Cell Therapy , Renal Transplant Recipients , Ton Rabelink , Internal Medicine , Chief Executive Officer , Professor Rabelink , Managing Director , Clinical Trial , Cynata Therapeutics , Therapeutics Limited , Key Highlights Cynata To Collaborate With Leiden University Medical Center Lumc In The Netherlands , Na New Clinical Trial In Patients Who Have Receiveda Kidney Transplant To Be Funded By Lumc Cynata Will Supply Ipsc Derived Cymerus Mesenchymal Stem Cells Mscs At Its Cost Facilitate The And Has Full Commercial Rights There Are Approximately 130 , 000 Kidney Transplants Around The World Each Year Transplantation Is Life Saving In Patients With Chronic Renal Failure And Frees Patient From Need For Dialysis Currently , Ifelong Immune Suppressive Therapy Is Required In Renal Transplant Patients To Reduce The Risk Of Rejection This Can Lead Increased Infections And Cancer Main Anti Drugs Are Also Directly Toxic Kidneys Previous Clinical Trials , Esenchymal Stromal Stem Cells Have Shown Potential To Enable The Early Withdrawal Of Anti Rejection Drugs In Renal Transplant Recipients Without Increased And With Preserved Function Melbourne , Nov 4 , 022 Prnewswire Cynata Therapeutics Limited Asx Quot Cyp Or , A Clinical Stage Biotechnology Company Specialising In Cell Therapeutics ,